Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Boston Scientific stock faces weaker fourth-quarter outlook

Guidance lowered New AI features Regulatory approval AI-generated analysis

πŸ“‰ Boston Scientific lowered its fourth-quarter sales outlook to a projected decline of 1% to 3% year over year following slower third-quarter growth.

πŸ’° Third-quarter net sales reached $5.138 billion, representing a modest 1.5% increase from the prior-year quarter.

πŸ“‰ Adjusted earnings per share fell to $0.73 in Q3 from $0.75 a year earlier, with GAAP EPS dropping to $0.40.

πŸ”’ An August cybersecurity incident disrupted operations and contributed to the company's decision to reduce its near-term sales guidance.

πŸ’Š Cardiovascular sales rose 1.9% while MedSurg sales increased 0.6% during the third quarter.

πŸš€ The company received U.S. clearances for StoneSmart kidney-stone technologies and an expanded SEISMIQ peripheral lithotripsy catheter.

πŸ”¬ Enrollment began in the Elite AF trial for the next-generation WATCHMAN Elite device to support its longer-term portfolio.

🀝 Boston Scientific entered a strategic collaboration with Heartflow on AI-assisted planning for coronary interventions.

πŸ“ˆ Full-year 2026 adjusted EPS is projected at $3.16 to $3.18 with reported sales growth of approximately 4.25%.

Bullish Signals
  • Boston Scientific received U.S. clearances for StoneSmart kidney-stone technologies and an expanded SEISMIQ peripheral lithotripsy catheter, expanding its product portfolio.
  • The company began enrolling patients in the Elite AF trial for the next-generation WATCHMAN Elite device, supporting its longer-term pipeline growth.
  • Boston Scientific entered a strategic collaboration with Heartflow on AI-assisted planning for coronary interventions to enhance procedural capabilities.
  • Cardiovascular sales rose 1.9% and MedSurg sales increased 0.6% in the third quarter, demonstrating resilience across key segments.
Risk Factors
  • Boston Scientific expects fourth-quarter sales to decline between 1% and 3% year over year due to slower growth momentum.
  • Adjusted earnings per share declined year over year in the third quarter, falling from $0.75 to $0.73.
  • An August cybersecurity incident disrupted operations, leading management to lower its near-term sales outlook.
Full Analysis
Boston Scientific reported slower third-quarter growth with net sales rising just 1.5% to $5.138 billion, while adjusted earnings per share declined year over year. The company subsequently lowered its near-term outlook, projecting a fourth-quarter sales decline between 1% and 3% compared to the prior-year quarter. Management forecasts full-year 2026 reported sales growth of approximately 4.25% and organic growth of roughly 3.75%, with adjusted EPS expected to range from $3.16 to $3.18. For the third quarter specifically, adjusted EPS is forecast at $0.77 to $0.79, following a drop to $0.73 in the previous quarter. The company cited an August cybersecurity incident that disrupted operations as a factor influencing its revised near-term sales outlook. Despite this operational pressure, Boston Scientific highlighted progress in its longer-term pipeline, including new device clearances for StoneSmart kidney-stone technologies and an expanded SEISMIQ peripheral lithotripsy catheter.